This is a working overview of mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-19 and is reviewed periodically as new material appears.
Reverse-phase high-performance liquid chromatography (RP-HPLC) is widely used to estimate peptide purity. It separates components by hydrophobicity on a column with a water-organic mobile phase. Ultraviolet absorbance at 214 nm or 220 nm detects peptide bonds. The main peak area as a percentage of total peak area gives a purity figure. This figure depends on column, gradient, wavelength, and how peaks are integrated, so it is method-specific rather than absolute.
Mass spectrometry provides complementary information by measuring molecular mass. Electrospray ionization or matrix-assisted laser desorption/ionization can confirm the expected peptide mass and reveal related impurities with different masses. It does not directly quantify all species because ionization efficiency varies. When coupled to liquid chromatography, LC-MS can assign masses to chromatographic peaks. This helps distinguish target peptide from truncation, oxidation, or deletion products. Mass accuracy and resolution determine how confidently a mass can be matched to a proposed structure.
Other methods address specific purity concerns. Amino acid analysis gives compositional data after hydrolysis, while capillary electrophoresis separates by charge-to-mass ratio. Karl Fischer titration measures residual water, and gas chromatography can detect residual solvents. Nuclear magnetic resonance can identify organic impurities but is less sensitive for trace levels. No single test covers all possible impurities, so purity testing usually combines orthogonal methods and reports the conditions used. The choice of methods is guided by the impurity classes of interest.
Quality control relies on predefined specifications rather than a single purity number. A certificate of analysis typically lists the test method, acceptance limit, and measured result for each attribute. Common specifications include appearance, peptide content, water content, counterion identity, and related substances. Limits are set according to the peptide's intended use and the capability of the analytical method. A result outside a limit triggers investigation, not automatic rejection, because method variability and sample handling can affect outcomes.
Sample handling influences measured purity. Lyophilized peptides are hygroscopic and can absorb water, changing weight-based calculations, while repeated freeze-thaw cycles may promote aggregation or degradation. Dissolved samples should be prepared fresh when possible and protected from light and heat. In purity testing, the same handling conditions should apply to standards and samples. Stability-indicating methods are designed to separate degradation products from the parent peptide, though open questions remain about how accelerated stability data predict long-term behavior for every sequence.
| Property | Value | Notes |
|---|---|---|
| Typical analytical method | RP-HPLC with UV detection | Separates by hydrophobicity; purity is method-dependent |
| Confirmatory method | LC-MS or MALDI-TOF MS | Provides molecular mass and impurity mass information |
| Common detection wavelength | 214 nm or 220 nm | Peptide bond absorbance; also 280 nm for aromatic residues |
| Typical purity specification | 95% or greater by HPLC area | Common research grade; exact threshold depends on application |
| Sample preparation | Dissolve in water/acetonitrile with acid | Formic acid or trifluoroacetic acid often used |
Reversed-phase high-performance liquid chromatography (RP-HPLC) is widely used to estimate peptide purity. Separation depends on interactions between peptide residues and a hydrophobic stationary phase, with gradients of water and organic solvent. Ultraviolet detection near 214 nm responds to the peptide backbone and to many related impurities. The resulting chromatogram is often expressed as area percent, which reports the proportion of peak area assigned to the main component. Different columns, gradients, and wavelengths can produce different purity values for the same material.
Mass spectrometry provides complementary information about molecular identity and certain impurities. Electrospray ionization and matrix-assisted laser desorption/ionization are common ionization techniques for peptides. A measured mass close to the expected value supports correct sequence length and modifications, while extra mass signals can reveal truncations, adducts, or incomplete deprotection. Mass spectrometry alone is not a quantitative purity assay, because ionization efficiency varies between compounds. Coupling liquid chromatography to mass spectrometry links retention time with mass and helps assign peaks that ultraviolet detection records.
Orthogonal separation methods address impurities that RP-HPLC may not resolve. Size-exclusion chromatography detects aggregates and higher-order species, while ion-exchange chromatography separates charge variants. Capillary electrophoresis can assess charge-to-mass ratios and, in some formats, size-based impurities. Amino acid analysis and nitrogen determination estimate peptide content rather than chromatographic purity. Because each technique has a different selectivity, a complete purity profile usually combines results from more than one method. The choice of method depends on the impurity classes of concern.
Quality control for peptide products relies on written procedures, batch records, and certificates of analysis. A certificate of analysis typically lists the test methods, specifications, and results for a specific lot. Batch records document synthesis, purification, and testing steps so that results can be traced to process conditions. Method validation establishes accuracy, precision, specificity, linearity, and limits of detection. These records support consistency across lots and allow laboratories to investigate deviations when a specification is not met.
Storage conditions influence purity and therefore testing outcomes. Lyophilized peptides are generally kept cool and dry, while solutions may require refrigeration or freezing depending on sequence and buffer. Repeated freeze-thaw cycles can promote aggregation, oxidation, or hydrolysis. Testing after storage should use the same validated method as release testing to allow comparison. Stability studies examine how purity changes over time under defined temperature and humidity conditions. Results are compared against baseline data collected at release.
Regulatory frameworks treat peptide purity as part of product quality, though requirements vary by intended use and jurisdiction. Investigational materials may need identity, strength, quality, and purity documentation. Compendial monographs, when available, specify tests and acceptance criteria for certain peptides. For research peptides, oversight is often less prescriptive, and buyers may rely on supplier documentation. Open questions remain about how to standardize impurity reporting across laboratories and how to define purity for complex or modified peptides.
Peptide purity specifications describe the minimum acceptable result from a defined test. A certificate of analysis may list HPLC purity, mass spectrometry identity, appearance, and counterion content. Specifications are method-dependent, so a value obtained with one gradient or wavelength may differ from another. For research use, common thresholds include 95% and 98% by RP-HPLC, but the appropriate limit depends on the application. The specification should always name the analytical method and acceptance criterion.
Quality control includes system suitability, blank injections, and reference standards. System suitability checks column performance and retention time reproducibility, while blank runs detect carryover or mobile-phase contaminants. Reference standards help calibrate retention time and detector response. Without these controls, a purity value is difficult to compare across laboratories or over time. Documentation of instrument settings and integration parameters is also part of quality control, and acceptance criteria should be set before samples are analyzed.
=== Usage in general public === A number of products are sold online and in gyms and beauty salons as "melanotan" or "melanotan-1" which discuss afamelanotide in their marketing. Without a prescription, these drugs are not legally sold in many jurisdictions and are potentially dangerous. Starting in 2007, health agencies in various countries began issuing warnings against their use.
== Causes == Cerebral hypoxia can be caused by any event that severely interferes with the brain's ability to receive or process oxygen. This event may be internal or external to the body. Mild and moderate forms of cerebral hypoxia may be caused by various diseases that interfere with breathing and blood oxygenation. Severe asthma and various sorts of anemia can cause some degree of diffuse cerebral hypoxia. Other causes include status epilepticus, work in nitrogen-rich environments, ascent from a deep-water dive, flying at high altitudes in an unpressurized cabin without supplemental oxygen, and intense exercise at high altitudes before acclimatization. Severe cerebral hypoxia and anoxia is usually caused by traumatic events such as choking, drowning, strangulation, smoke inhalation, drug overdoses, crushing of the trachea, status asthmaticus, and shock. It is also recreationally self-induced in the fainting game and in erotic asphyxiation.
1993/2568) Portsmouth Health Care National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2569) Riverside Community Health Care National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2570) Robert Jones and Agnes Hunt Orthopaedic and District Hospital National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2571) Rockingham Forest National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2572) Royal Shrewsbury Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2573) Royal Wolverhampton Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2574) Salisbury Health Care National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2575) Solihull Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2576) Stoke Mandeville Hospital National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2577) Wandsworth Community Health National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2578) Warwickshire Ambulance Service National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2579) South Warwickshire Mental Health National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2580) Winchester and Eastleigh Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2581) Worcester Royal Infirmary National Health Service Trust (Establishment) Order 1993 (S.I. 1993/2582) Chichester Priority Care Services National Health Service Trust (Establishment) Order 1993 (S.I.
=== Pharmacokinetics === The half-life of melarsoprol is less than one hour, but bioassays indicate a 35-hour half-life. This is commonly associated with pharmacologic agents that have active metabolites. One such metabolite, melarsen oxide, reaches maximum plasma levels about 15 minutes after melarsoprol injection. Melarsoprol clearance is 21.5 ml/min/kg and the half-life of melarsen oxide is approximately 3.9 hours.
Sources: en.wikipedia.org
=== Acquired antithrombin deficiency === Acquired antithrombin deficiency occurs as a result of three distinctly different mechanisms. The first mechanism is increased excretion which may occur with renal failure associated with proteinuria nephrotic syndrome. The second mechanism results from decreased production as seen in liver failure or cirrhosis or an immature liver secondary to premature birth. The third mechanism results from accelerated consumption which is most pronounced as consequence of severe injury trauma but also may be seen on a lesser scale as a result of interventions such as major surgery or cardiopulmonary bypass.
It was not long before Maximilien de Robespierre and the now dominant Jacobin Club turned against the radical factions of the National Convention, including the sans-culottes, despite their having previously been the strongest supporters of the revolution and its government. Several important leaders of the Enragés and Hébertists were imprisoned and executed by the very revolutionary tribunals they had supported. The execution of radical leader Jacques Hébert spelled the decline of the sans-culottes, and with the successive rise of even more conservative governments, the Thermidorian Convention and the French Directory, they were definitively silenced as a political force. After the defeat of the 1795 popular revolt in Paris, the sans-culottes ceased to play any effective political role in France until the July Revolution of 1830.
Mel's Drive-In refers to two American restaurant chains, the successors of a chain founded in 1947 by Mel Weiss and Harold Dobbs in San Francisco, California. The original chain operated until the 1970s. A new generation of Mel's Drive-In restaurants then began opening in the 1980s, with the business split into two separate groups: one doing business under the original Mel's Drive-In name and the other under the name Original Mels. Mel's Drive-In became closely associated with the 1973 film American Graffiti after one of its restaurants was used as a filming location. The film's distributor, Universal Studios, licensed the Mel's Drive-In brand to recreate the restaurants in its Universal theme parks. The signage and menus on the original Mel's Diners did not have a possessive apostrophe in the name, as would be expected. However, Universal Studios opted to include the apostrophe in all Mel's Drive-In signage, literature, and media.
Sources: en.wikipedia.org
It usually refers to the relative area of the main peak in a chromatographic separation, such as RP-HPLC. It estimates the proportion of UV-absorbing material in that peak, not the absolute mass fraction of the target peptide. Different methods can give different percentages.
HPLC separates and quantifies components, while mass spectrometry identifies molecular masses. Together they can show whether a main peak has the expected mass and whether other peaks correspond to related peptide variants. This combination is more informative than either method alone.
Higher purity reduces the proportion of detectable related impurities, which can matter for research reproducibility. However, purity value alone does not establish identity, biological activity, or safety. The appropriate purity depends on the intended use and the sensitivity of the assay.
A related substance is a peptide-like impurity that resembles the target sequence, such as a truncated or modified form. It is often reported as individual and total area percent.